ARCHIVES

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

Spending Measures Include Provisions On Ethics For NIH Extramural Scientists.

July 11, 2008

NIH Cool On OIG, But the Awardees Love it, DeVita Says

October 17, 1986

First Report On Carcinogens Now Avaiable

October 3, 1980

Alan Rabson Named Acting NCI Director

October 5, 2001

Cancer Groups Urge FDA To Spell Out Standards For Data Collection In Time-To-Progression Trials.

November 7, 2008

New CEO Brings Managed Care Expertise To Network Of Academic Cancer Centers

January 24, 1997